Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

134.81 +1.68 (+1.26%)
Streaming Delayed Price Updated: 2:00 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
51 52 Next >
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Biogen Moves Deeper In Alzheimer's With Denali
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies? 
Via Talk Markets
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement 
From Denali Therapeutics Inc.
Via GlobeNewswire
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
12 Analysts Have This to Say About Biogen
Via Benzinga
3 Biotech Stocks to Watch for Potential Breakthroughs
These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future. 
Via InvestorPlace
Twitter Inc Is Officially Defunct, Alibaba Plans to Integrate ChatGPT Like Chatbot Across Products, Moderna's Flu Shot Study Misses 'Early Success' Criteria: Today's Top Stories
Benzinga Twitter Inc Is Officially Defunct As Elon Musk Pursues' Superapp' Goal 
Via Benzinga
A Look Into Biogen's Debt
Via Benzinga
Price Over Earnings Overview: Biogen
Via Benzinga
Biogen Unusual Options Activity
Via Benzinga
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension
Via Benzinga
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
Shares are closing in on a buy point out of a consolidation. 
Via Investor's Business Daily
The 3 Best Millionaire-Maker Stocks to Buy for April 2023
These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Biogen Appoints Adam Keeney as Head of Corporate Development
From Biogen Inc.
Via GlobeNewswire
11 Analysts Have This to Say About Biogen
Via Benzinga
Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories
Bloomberg UBS Prepping For Massive Layoffs Amid Credit Suisse Takeover 
Via Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer... 
Via Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Via Benzinga
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
From Biogen Inc.
Via GlobeNewswire
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
7 Blue-Chip Stocks Sitting in the Sweet Spot
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23
Looking for longs after a clear resumption of the uptrend. 
Via Talk Markets
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
Via Benzinga
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States 
From Biogen Inc.
Via GlobeNewswire
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
Interested in investing in iMetabolic BioPharma? Click here to get started! 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.